Evaluation of the cardiovascular risk in patients undergoing major non-cardiac surgery : role of cardiac-specific biomarkers
© 2022 Walter de Gruyter GmbH, Berlin/Boston..
Major adverse cardiovascular events are frequently observed in patients undergoing major non-cardiac surgery during the peri-operative period. At this time, the possibility to predict cardiovascular events remains limited, despite the introduction of several algorithms to calculate the risk of adverse events, mainly death and major adverse cardiovascular events (MACE) based on the clinical history, risk factors (sex, age, lipid profile, serum creatinine) and non-invasive cardiac exams (electrocardiogram, echocardiogram, stress tests). The cardiac-specific biomarkers natriuretic peptides (NPs) and cardiac troponins (cTn) have been proposed as additional tools for risk prediction in the peri-operative period, particularly for the identification of myocardial injury in patients undergoing major non-cardiac surgery. The prognostic information from the measurement of BNP/NT-proBNP and hs-cTn is independent and complementary to other important indicators of risk, also including ECG and imaging techniques. Elevated levels of cardiac-specific biomarkers before surgery are associated with a markedly higher risk of MACE during the peri-operative period. BNP/NT-proBNP and hs-cTn should be measured in all patients during the clinical evaluation before surgery, particularly during intermediate- or high-risk surgery, in patients aged >65 years and/or with comorbidities. Several questions remain to be assessed in dedicated clinical studies, such as how to optimize the management of patients with raised cardiac specific biomarkers before surgery, and whether a strategy based on biomarker measurement improves patient outcomes and is cost-effective.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:60 |
|---|---|
| Enthalten in: |
Clinical chemistry and laboratory medicine - 60(2022), 10 vom: 27. Sept., Seite 1525-1542 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Clerico, Aldo [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 30.08.2022 Date Revised 12.10.2022 published: Electronic-Print Citation Status MEDLINE |
|---|
| doi: |
10.1515/cclm-2022-0481 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM343782987 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM343782987 | ||
| 003 | DE-627 | ||
| 005 | 20231226021241.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1515/cclm-2022-0481 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1145.xml |
| 035 | |a (DE-627)NLM343782987 | ||
| 035 | |a (NLM)35858238 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Clerico, Aldo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Evaluation of the cardiovascular risk in patients undergoing major non-cardiac surgery |b role of cardiac-specific biomarkers |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.08.2022 | ||
| 500 | |a Date Revised 12.10.2022 | ||
| 500 | |a published: Electronic-Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 Walter de Gruyter GmbH, Berlin/Boston. | ||
| 520 | |a Major adverse cardiovascular events are frequently observed in patients undergoing major non-cardiac surgery during the peri-operative period. At this time, the possibility to predict cardiovascular events remains limited, despite the introduction of several algorithms to calculate the risk of adverse events, mainly death and major adverse cardiovascular events (MACE) based on the clinical history, risk factors (sex, age, lipid profile, serum creatinine) and non-invasive cardiac exams (electrocardiogram, echocardiogram, stress tests). The cardiac-specific biomarkers natriuretic peptides (NPs) and cardiac troponins (cTn) have been proposed as additional tools for risk prediction in the peri-operative period, particularly for the identification of myocardial injury in patients undergoing major non-cardiac surgery. The prognostic information from the measurement of BNP/NT-proBNP and hs-cTn is independent and complementary to other important indicators of risk, also including ECG and imaging techniques. Elevated levels of cardiac-specific biomarkers before surgery are associated with a markedly higher risk of MACE during the peri-operative period. BNP/NT-proBNP and hs-cTn should be measured in all patients during the clinical evaluation before surgery, particularly during intermediate- or high-risk surgery, in patients aged >65 years and/or with comorbidities. Several questions remain to be assessed in dedicated clinical studies, such as how to optimize the management of patients with raised cardiac specific biomarkers before surgery, and whether a strategy based on biomarker measurement improves patient outcomes and is cost-effective | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a acute myocardial infarction | |
| 650 | 4 | |a cardiac natriuretic peptides | |
| 650 | 4 | |a cardiac troponins | |
| 650 | 4 | |a cardiovascular risk | |
| 650 | 4 | |a major non-cardiac surgery | |
| 650 | 4 | |a myocardial injury | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Peptide Fragments |2 NLM | |
| 650 | 7 | |a Natriuretic Peptide, Brain |2 NLM | |
| 650 | 7 | |a 114471-18-0 |2 NLM | |
| 700 | 1 | |a Zaninotto, Martina |e verfasserin |4 aut | |
| 700 | 1 | |a Aimo, Alberto |e verfasserin |4 aut | |
| 700 | 1 | |a Musetti, Veronica |e verfasserin |4 aut | |
| 700 | 1 | |a Perrone, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Padoan, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Dittadi, Ruggero |e verfasserin |4 aut | |
| 700 | 1 | |a Sandri, Maria Teresa |e verfasserin |4 aut | |
| 700 | 1 | |a Bernardini, Sergio |e verfasserin |4 aut | |
| 700 | 1 | |a Sciacovelli, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Trenti, Tommaso |e verfasserin |4 aut | |
| 700 | 1 | |a Malloggi, Lucia |e verfasserin |4 aut | |
| 700 | 1 | |a Moretti, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Burgio, Maria Aurora |e verfasserin |4 aut | |
| 700 | 1 | |a Manno, Massimiliano Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Migliardi, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Fortunato, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Plebani, Mario |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical chemistry and laboratory medicine |d 1998 |g 60(2022), 10 vom: 27. Sept., Seite 1525-1542 |w (DE-627)NLM095304118 |x 1437-4331 |7 nnns |
| 773 | 1 | 8 | |g volume:60 |g year:2022 |g number:10 |g day:27 |g month:09 |g pages:1525-1542 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1515/cclm-2022-0481 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 60 |j 2022 |e 10 |b 27 |c 09 |h 1525-1542 | ||